NASD · Healthcare · Medical Devices · USA
Axogen Inc is a mid cap company (market value between $2 billion and $10 billion) in the Medical Devices industry.
Axogen develops and commercializes technologies for peripheral nerve repair and regeneration. The company offers a portfolio of products including nerve allografts, nerve connectors, nerve protectors, and tissue matrices used by surgeons to repair damaged peripheral nerves caused by trauma or surgical procedures. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Axogen Inc stock.
Overvalued: intrinsic value $9.95 per share, market price $36.17, margin of safety -263.4% (as of 2026-10-20).
A 2.4x revenue multiple, discounted for its losses, values the shares at $9.95; the price of $36.17 is 263% above that value.
Leak Score: 35/100 on 10 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 142 Medical Devices stocks
47 more in this industry show a wider margin of safety.
AXGN is overvalued (as of the 2026-10-20 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $9.95; the price of $36.17 is 263% above that value.
$9.95 per share (as of the 2026-10-20 close), against a market price of $36.17. That is a margin of safety of -263.4%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
35 out of 100, which we rate "On Watch", on 10 of 12 value investing signals.